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Overview- One hundred and ten years since its first description Alzheimer’s disease
(AD) still retains its prominent status: (i) as the industrialized world’s number one cause of
age-related intellectual impairment and cognitive decline; (ii) as this country’s most rapidly
expanding socioeconomic and healthcare concern; and (iii) as an insidious, progressive
and lethal neurological disorder of the human central nervous system (CNS) for which
there is currently no adequate treatment or cure (Alzheimer, 1991; Alzheimer et al.,
1991, 1995) [https://www.alz.org/facts/downloads/facts_figures_2015.pdf (2015)]. The
concept of small non-coding RNAs (ncRNAs) as being involved in the etiopathogenesis
of AD and age-related human neurodegenerative disease was first proposed about 25
years ago, however it was not until 2007 that specific microRNA (miRNA) abundance,
speciation and localization to the hippocampal CA1 region (an anatomical area of the
human CNS specifically targeted by the AD process) was shown to strongly associate
with AD-type change when compared to age-matched controls (Lukiw et al., 1992;
Lukiw, 2007; Schipper et al., 2007; Cogswell et al., 2008; Guerreiro et al., 2012).
Currently about 400 reports address the potential link between disruptions in miRNA
signaling and the development of various features associated with AD neuropathology
(http://www.ncbi.nlm.nih.gov/pubmed/?term=micro+RNA+alzheimer’s+disease). In
this “Perspectives” paper we will highlight some of the most recent literature on
anti-miRNA (AM; antagomir) therapeutic strategies and some very recent technological
advances in the analysis and characterization of defective miRNA signaling pathways in
AD compared to neurologically normal age-matched controls.
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THE microRNA (miRNA) MECHANISM IN HEALTH AND
DISEASE—WHAT THE NUMBERS ARE TELLING US
Firstly, miRNAs are generated within the nucleus by an RNA Polymerase II (RNA Pol II)-
mediated transcription mechanism yielding a long “primary” miRNA precursor thousands of
nucleotides (nt) in length which are subsequently processed to produce a second miRNA precursor
(pre-miRNA) of 60–100 nt. This pre-miRNA next translocates to the cytoplasm where it is
further processed by an RNase-III type endoribonuclease and associated ribonuclear proteins to
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generate a final mature ∼22 nt miRNA product (Ambros
et al., 2003; Ambros, 2004; Burmistrova et al., 2007; Bartel,
2009; Lukiw, 2012; Jiang et al., 2013; Lukiw et al., 2013;
Pogue et al., 2014; Qiu et al., 2014; Denzler and Stoffel,
2015; Fang and Bartel, 2015; Femminella et al., 2015; Karnati
et al., 2015; Wu et al., 2015; Zhao et al., 2015; Roth et al., 2016)
[http://www.lcsciences.com/applications/transcriptomics/mirna-
profiling/mirna/ (2015)]. The initial generation of the long
“primary” miRNA, the translocation of miRNA from nucleus
to cytoplasm; the “gating” of pre-miRNA precursor through
the nuclear pore, the pre-miRNA and the actual mature
miRNA ribonucleotide sequence are all potentially important
nodes of anti-miRNA- (AM)-based inhibition (Bartel, 2009;
Guo et al., 2010; Lukiw, 2012; Denzler and Stoffel, 2015;
Fang and Bartel, 2015; Karnati et al., 2015). There are about
2650 mature human miRNAs currently recognized using
existing technologies that include, most recently, microfluidic
miRNA array and RNA sequencing, and probably not many
more novel mature miRNA sequences will be discovered
(Burmistrova et al., 2007; Jiang et al., 2013; Lukiw et al., 2013)
[http://www.lcsciences.com/applications/transcriptomics/mirna-
profiling/mirna/ (2015)]. What is remarkable is the
relatively small number of abundant miRNAs in the
human CNS which currently number only about 40–50
(Jiang et al., 2013; Lukiw et al., 2013; Qiu et al., 2014;
Femminella et al., 2015; Zhao et al., 2015; Roth et al., 2016)
[http://www.lcsciences.com/applications/transcriptomics/mirna-
profiling/mirna/ (2015)]. This in itself represents a tremendous
evolutionary selection pressure in that only ∼1.5% of all known
miRNAs have been selected to function in productive gene
expression regulation in the brain and CNS (Pogue et al., 2014).
For example, miRNA-854, a modulator of the expression of
the oligouridylate (oligo-UTP) binding protein 1b (UTPBP1b)
has been conserved between Arabidopsis thaliana and the
brain of Homo sapiens for ∼1.5 billion years; few nucleic acids,
proteins or other molecular markers of any type have been
perfectly conserved between plants and animals for such a
long period of time (Lukiw, 2012; Pogue et al., 2014; Zhao
et al., 2015). Another interesting consideration is that a ∼22
nucleotide (nt) single-stranded ncRNA composed of 4 different
ribonucleotides—(adenine, guanine, cytosine or uridine; A, G,
C, U)—has the potential to form well over 1013 possible ∼22
oligonucleotide sequence combinations. The fact that there are
only about 2.65 × 103 different miRNAs in the entire human
body again suggests an extremely high evolutionary selection
pressure to utilize only specific ribonucleotide sequences in
miRNAs that will yield neuro-biologically useful micro RNA–
messenger RNA (miRNA–mRNA) interactions (Ambros et al.,
2003; Ambros, 2004; Bartel, 2009; Lukiw, 2012; Denzler and
Stoffel, 2015; Fang and Bartel, 2015; Karnati et al., 2015; Wu
et al., 2015). Put another way, just about one in ten billion
potential miRNA sequences have found a useful purpose in
miRNA-mRNA-based gene regulation in human metabolic and
developmental physiology, and less than one in two-hundred
billion potential miRNA sequences have found a useful purpose
in miRNA-mRNA-based gene regulation in the human brain
(Bartel, 2009; Lukiw, 2012; Denzler and Stoffel, 2015; Fang
and Bartel, 2015). It is an interesting question to ask if these
exceptionally unique miRNA sequences in the brain are the
common denominator of some CNS gene-regulatory network
that we are just beginning to understand. Fromwhat we currently
know, of the 40–50 abundant miRNAs detected in the “normally
aging” control brain and retina only about one-quarter to
one-fifth are significantly up-regulated in the AD brain, and
this has important implications on the therapeutic design
for managing the abundance of that family of pathologically
up-regulated miRNAs in the degenerating CNS (Burmistrova
et al., 2007; Jiang et al., 2013; Lukiw et al., 2013; Qiu et al.,
2014; Femminella et al., 2015; Zhao et al., 2015; Roth et al., 2016)
[http://www.lcsciences.com/applications/transcriptomics/mirna-
profiling/mirna/ (2015)].
PATHOLOGICALLY UP-REGULATED
miRNAs LEAD TO PATHOLOGICALLY
DOWN-REGULATED mRNAs
While our insights into the neurobiological mechanism and
relevance of miRNA signaling continues to evolve, it is now
generally accepted that the primary mode of miRNA action is
to recognize and bind to specific complementary ribonucleotide
sequences in the 3′ untranslated region (3′UTR) of target
messenger RNAs (mRNAs), and in doing so, down-regulate
their expression (Bartel, 2009; Guo et al., 2010; Lukiw, 2012;
Denzler and Stoffel, 2015; Fang and Bartel, 2015; Karnati et al.,
2015). Interestingly, multiple independent studies from different
laboratories whose research focuses on brain gene expression
patterns indicate that in sporadic AD about 1/3 of all brain genes
are up-regulated and about 2/3 of all brain genes are down-
regulated (Loring et al., 2001; Colangelo et al., 2002; Lukiw,
2004; Ginsberg et al., 2012). The generalized up-regulation of the
potent transcriptional activator NF-kB in AD brain was therefore
somewhat perplexing since NF-kB is known as a strong inducer
of inflammatory gene expression (Lukiw and Bazan, 1998; Lukiw
et al., 2008; Cui et al., 2010; Devier et al., 2015; Kaur et al.,
2015; Srinivasan and Lahiri, 2015). Interestingly most of the
up-regulated pathogenic, pro-inflammatory genes in sporadic
AD brain are directly under NF-kB transcriptional control,
while down-regulated mRNAs and their expression appear to
be under negative regulatory control by miRNAs which have
NF-kB regulatory sites in their promoters (Figure 1; Lukiw and
Bazan, 1998; Lukiw et al., 2008; Cui et al., 2010; Lukiw, 2012a,b,
2013a; Devier et al., 2015; Kaur et al., 2015; Srinivasan and Lahiri,
2015). Indeed the observed upregulation of multiple miRNAs
in neurodegenerative disorders such as AD may in part explain
the large number of brain gene mRNAs that are found to be
consistently down-regulated in anatomical regions of the human
brain targeted by the AD process (Loring et al., 2001; Colangelo
et al., 2002; Lukiw, 2004; Ginsberg et al., 2012).
PATHOGENIC miRNAs—UP- AND
DOWN-REGULATION OR “DE NOVO”
APPEARANCE
It has been almost 10 years since the first reports of altered
miRNA abundance and speciation: (i) in anatomical regions
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FIGURE 1 | Schematic diagram illustrating pathogenic signaling
circuits in sporadic AD brain and potential therapeutic strategies for
intervention. Recent observations suggest the presence of a cyclical
and self-reinforcing pathogenic “AD relevant stressor(s)-NF-kB-
miRNA-mRNA-gene expression loop” in AD brain; this signaling
pathway may be amenable to anti-miRNA (AM) and/or NF-kB inhibitor
therapeutic strategies that in theory should help restore homeostatic
gene expression to the damaged brain. Sporadic AD relevant stressors
include age, diet (such as high fat-cholesterol intake), environmental, lifestyle,
exposure to viruses (such as HCV or HSV-1), environmental toxins (such as
aluminum), epilepsy, prions, and other neurological diseases and other factors;
each of these AD-relevant stressors are known induce NF-kB signaling (Lukiw
et al., 2008; Cui et al., 2010; Lukiw, 2012a,b, 2013a; Hill et al., 2015b;
Srinivasan and Lahiri, 2015; Yuan et al., 2015); NF-kB signaling has been
observed to be generally up-regulated in AD brain that subsequently
up-regulates the transcription from NF-kB sensitive pro-inflammatory miRNA
promoters (Lukiw and Bazan, 1998; Lukiw et al., 2008; Cui et al., 2010; Devier
et al., 2015; Kaur et al., 2015; Srinivasan and Lahiri, 2015); in turn
up-regulated miRNAs generally down-regulate their mRNA targets; for
example miRNA-146a, a well characterized pro-inflammatory miRNA contains
three active canonical NF-kB recognition features in its promoter (Lukiw et al.,
2008; Cui et al., 2010); up-regulated miRNAs may pathologically
down-regulate a family of AD relevant mRNAs that are involved in
synaptogenesis, neurotrophism, the innate-immune response, inflammation
and amyloidogenesis (Loring et al., 2001; Cogswell et al., 2008; Kaur et al.,
2015; Srinivasan and Lahiri, 2015). It has been possible, for example, to
throttle-up or throttle down miRNA-146a expression in AD primary brain cell
culture models using AD-relevant inducers or combinations of AM
ribonucleotide sequences and NF-kB inhibitors (Lukiw et al., 2008; Cui et al.,
2010; Lukiw, 2012a, 2013a). AD-relevant stressors and NF-kB may also
directly induce pro-inflammatory mRNAs that possess NF-kB binding sites in
their immediate promoters. While it may be difficult to reduce lifelong exposure
to AD relevant stressors it may be possible (i) to specifically inhibit miRNA
up-regulation using anti-miRNA (AM) ribonucleotide sequences 100%
complementary to up-regulated brain miRNAs, and/or (ii) to directly inhibit
NF-kB up-regulation (several hundred NF-kB inhibitors are known). The
intrinsic problem with excessive NF-kB inhibition is that many homeostatic cell
processes rely on NF-kB signaling so the potential for unwanted off-target
effects using NF-kB inhibitors may be both severe and numerous
(Continued)
FIGURE 1 | Continued
(Lukiw, 2012a,b, 2013a; Yuan et al., 2015). The actions of miRNA signaling
may in turn modulate NF-kB signaling. Overall, it may be a better strategy to
inhibit miRNAs using highly specific and selective AM sequences to target just
a single or a few miRNA-mRNA-mediated signaling pathways, particularly
those which are the most significantly up-regulated in AD brain. The
combinatorial use of AM strategies and NF-kB inhibitors may turn out to be
the most effective in the clinical management of AD, and their stoichiometry
may need to be carefully adjusted to meet the needs of individual AD patients
(Lukiw et al., 2008; Cui et al., 2010; Lukiw, 2012a,b, 2013a; Srinivasan and
Lahiri, 2015; Yuan et al., 2015). The efficient delivery of AM ribonucleotide
sequences remains a challenging therapeutic problem (Janssen et al., 2013;
Zhang et al., 2013; Brites and Fernandes, 2015; Kang et al., 2015; Properzi
et al., 2015; Wang et al., 2015; van der Pol et al., 2016).
of the brain targeted by the AD process after post-mortem
examination, (ii) in blood serum, and (iii) in cerebrospinal fluid
(CSF; Lukiw, 2007; Schipper et al., 2007; Cogswell et al., 2008).
Since then an in depth overview of the peer-reviewed literature
has provided no general consensus of what miRNAs are up-
or-down regulated in any tissue or biofluid compartment in
many thousands of AD patients (Sethi and Lukiw, 2009; Hill and
Lukiw, 2015; Sanei and Chen, 2015). To treat AD using an AM
approach we must first be certain that our miRNA targets are
really up- or down-regulated and not the consequence of some
artefactual analytical technique or sample-based concern. It is
clear that there are really three kinds of mature miRNA classes
in human disease: (i) those that are already being expressed
and their expression is down-regulated in the disease state; (ii)
those that are already being expressed and their expression is
upregulated in the disease state; and (iii) those whose expression
appears “de novo” and their new expression correlates to the
“onset” or “emerging presence” of the disease state (Sethi and
Lukiw, 2009; Ramsingh et al., 2010; Gabriely et al., 2011; Hill
and Lukiw, 2015; Leung, 2015; Sanei and Chen, 2015; Yuan
et al., 2015). In the study of miRNAs in human post-mortem AD
tissues it is probably a sensible idea to avoid the study of down-
regulated miRNAs as their “down-regulation” may be relevant
to the relatively short half-life (∼1–3 h) of miRNAs in AD
tissues and their “reduced presence” under pathophysiological
intracellular conditions which promote the rapid degeneration of
neuromolecular components (Sethi and Lukiw, 2009; Ramsingh
et al., 2010; Hill and Lukiw, 2015; Sanei and Chen, 2015).
The study of “up-regulated miRNAs” in AD is probably a
better choice since if these miRNAs are still up-regulated in the
intensively degradative cellular environment of AD tissues, then
their up-regulation is probably real and non-artefactual (Sethi
and Lukiw, 2009; Ramsingh et al., 2010; Hill and Lukiw, 2015;
Sanei and Chen, 2015). No miRNA has yet been identified in AD
that appears “de novo” with the initiation or onset of the disease,
in contrast to certain cancer-associated miRNAs such as miRNA-
10b or miRNA-33 that appear to be previously silent or quiescent
and subsequently are “super-activated,” i.e., up-regulated from
zero-abundance, such as is seen in malignant glioblastoma brain
tumors and the onset of gliomagenesis [(Gabriely et al., 2011;
Teplyuk et al., 2012; unpublished data); AMKrichevsky, personal
communication]. The abundance of miRNAs measured in brain
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biopsies, in blood serum or in the CSF of AD patients, which
can be obtained in 1 h or less, are not as prone to this
post-mortem related miRNA instability problem, and may be
the method of choice when ascertaining actually what miRNA
species are dysregulated over the initiation and course of the
AD process. Importantly, because of human genetic individuality
the profile of these up- and/or down-regulated miRNAs appear
to differ between one AD patient and the next, however a
“personalized miRNA profile” may be a characteristic feature
for each individual AD patient and thus serve as a blueprint for
AM-based therapeutic strategies (see below).
THROTTLE UP AND THROTTLE
DOWN—SEED SEQUENCES AND
VARIABLE INHIBITION
In higher eukaryotes the recognition of the mRNA’s non-
coding 3′untranslated region (3′UTR) by miRNA via base pair
complementarity is modulated by an essential “seed sequence”
essential for the binding of the mature miRNA to the target
mRNA. This seed sequence is typically a conserved heptameric
ribonucleotide sequence most often situated at positions 2
through 7 from the miRNA’s 5′-end (Bartel, 2009; Denzler
and Stoffel, 2015; Fang and Bartel, 2015; Karnati et al., 2015).
Although base pairing of a miRNA and its target mRNA
3′UTR do not perfectly match over the ∼21–25 nt of the
unique miRNA sequence, the “seed sequence” is always perfectly
complementary (Sethi and Lukiw, 2009; Blennow et al., 2015;
Hill and Lukiw, 2015; Sanei and Chen, 2015). Along the same
lines of reasoning it may be possible to use AM sequences of
variable complementarity to their up-regulated miRNA targets
to achieve a “throttling down effect” on their expression and
ultimate physiological effects to achieve the desired therapeutic
endpoint. Put another way the ribonucleotide sequence of the
AMmay be engineered to not completely match that of its target
miRNA with the goal of not totally quenching the expression of
its target miRNA but rather only to down-regulate its abundance
to achieve a desired therapeutic outcome. The situation would be
similar for bona-fide down-regulated miRNAs in that protected
miRNAs with extended stabilities may be added to the system
to achieve the desired therapeutic result. Tailoring the dose and
stability of the AM (or exogenously added stabilized miRNA)
may also be of use in obtaining the most efficacious and sought
after pharmacological effect (Sethi and Lukiw, 2009; Monteys
et al., 2014; Baumgart et al., 2015; Blennow et al., 2015; Hill and
Lukiw, 2015; Sanei and Chen, 2015) (see below).
NF-kB INHIBITORS, anti-miRNA (AM)
DELIVERY SYSTEMS AND PATHOGENIC
GENE EXPRESSION
A considerable amount of independent laboratory research
data recently generated has come to the same conclusion
that the pro-inflammatory transcription factor NF-kB (p50/p65
dimer) is a powerful disruptor of normal homeostatic gene
expression functions in the AD brain, and other progressive age-
related neurodegenerative diseases. These include the significant
enhancement in the transcription of certain brain miRNAs
and the inducible up-regulation of their expression by NF-kB
(Lukiw and Bazan, 1998; Lukiw et al., 2008; Cui et al., 2010;
Lukiw, 2012a,b, 2013a; Devier et al., 2015; Kaur et al., 2015;
Srinivasan and Lahiri, 2015). Interestingly, while NF-kB regulates
the expression of multiple miRNAs, the expression and activity
of NF-kB can be directly or indirectly up-regulated or down-
regulated by various miRNAs; the reciprocal regulation between
miRNAs and NF-kB existing in the form of multiple positive and
negative feedback loops in various disease states has been recently
reviewed in depth (Yuan et al., 2015). Because a particularly
pathogenic set of AD-relevant pro-inflammatorymiRNAs appear
to be under NF-kB-mediated transcriptional control it seems
reasonable to speculate that in addition to AM strategies, NF-
kB inhibitors may play some future role in novel therapeutic
strategies to address neurodegenerative diseases in general and
to AD in particular (Lukiw et al., 2008; Cui et al., 2010; Lukiw,
2012a,b, 2013a; Devier et al., 2015; Kaur et al., 2015; Srinivasan
and Lahiri, 2015).
While the use of NF-kB inhibitor(s) and AM directed
strategies represent an obvious therapeutic choice in the future
clinical management of AD and related neurological disorders
for which miRNAs are now known to play critical pathological
roles, the delivery systems used to administer these drugs to the
AD patient are often complicated and problematic. For example,
suitable protective drug carriers containing NF-kB-inhibitory
and/or AM cargos, perhaps in combination with other drugs,
may be required and these kinds of “drug cocktail” strategies
are being widely researched for optimization of effective drug
delivery in cancer therapeutics (Janssen et al., 2013; Lau et al.,
2014; Gui et al., 2015; Kang et al., 2015; Properzi et al., 2015; Shi,
2015; Srivastava et al., 2015).
Chemical modifications of miRNAs including their use as
locked nucleic acids (LNAs) significantly prolongs miRNA half-
life and stability both in vitro and in vivo (Bartel, 2009;
Lukiw, 2012; Monteys et al., 2014; Denzler and Stoffel, 2015;
Fang and Bartel, 2015; Karnati et al., 2015). In a related
application, LNAs have been used to synthesize the first miRNA-
targeted drug Miravirsen©, an inhibitor of the liver-specific
miRNA-122 normally essential to hepatitis C virus (HCV)
replication (Janssen et al., 2013). In the last 2 years the use of
small, naturally occurring or engineered membrane-enveloped
nanovesicles called exosomes represent a novel approach to drug
delivery and disease management (Kang et al., 2015; Properzi
et al., 2015; Shi, 2015; Srivastava et al., 2015). Several excellent
recent reviews are available on LNA-based, nanovesicle and
related miRNA delivery systems and the interested reader is
encouraged to access and reference these recently compiled
volumes (Janssen et al., 2013; Gui et al., 2015; Kang et al., 2015;
Properzi et al., 2015; Shi, 2015; Srivastava et al., 2015; van der Pol
et al., 2016).
THE HETEROGENEOUS NATURE OF
miRNA EXPRESSION IN AD BRAIN
Lastly, sporadic AD involves the progressive age-related mis-
regulation of numerous neurobiological pathways at multiple
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molecular, genetic, epigenetic, behavioral, cognitive, mnemonic,
neurochemical, and neurophysiological stages. If advanced next
generation RNA-sequencing and/or high density microfluidic
array-based profiles of AD tissues or biofluid samples are
any indication of AD variability then there are real and
significant differences in AD onset, incidence, epidemiology,
disease course, severity, and progression amongst different
human populations (Guerreiro et al., 2012; Lukiw, 2013b; Qiu
et al., 2014; Walhovd et al., 2014; Barnes et al., 2015; Blennow
et al., 2015; Verhülsdonk et al., 2015; Wang et al., 2015; Zhao
et al., 2015; Roth et al., 2016). It is therefore unlikely that any
single miRNA in the CSF, blood serum or any other biofluid
compartments from multiple human populations will represent
an equal therapeutic target for every case of AD, and it would be
equally unlikely that any single AM strategy would be applicable
to the clinical management of every AD patient. Indeed, the
data continues to accumulate that not just a single miRNA,
but rather small families of pathogenic miRNAs, are probably
involved in the multiple neurobiological, neurochemical and
neurogenetic defects that characterize the AD process, and
different miRNA families may be co-localized to different regions
of brain tissue, exosome, blood serum, or CSF compartments
(Lau et al., 2014; Gui et al., 2015; Hill et al., 2015a,b; Shi,
2015; Srivastava et al., 2015; Wu et al., 2015; van Harten et al.,
2015). What might be particularly advantageous, however, for
significantly improved future sporadic AD therapeutics would
be a highly interactive, “personalized medicine” approach. This
would involve a comprehensive evaluation of multiple AD
deficiencies including, prominently, miRNA- and mRNA-based
gene expression alterations, AD-relevant DNA mutations, pro-
inflammatory biomarkers, and amyloid-peptide load in the CSF,
blood serum and other biofluids, combined with data fromMRI-
and PET-based brain imaging, and familial and clinical history
and lifestyle factors that together would be extremely useful in the
improvement of directed therapeutic strategies (Lau et al., 2014;
Walhovd et al., 2014; Baumgart et al., 2015; Blennow et al., 2015;
Gui et al., 2015; Hill et al., 2015a,b; Østergaard et al., 2015; van
Harten et al., 2015; Verhülsdonk et al., 2015; Wang et al., 2015;
Wu et al., 2015). Anti-miRNA (AM) therapeutic approaches
seem particularly attractive since alteration inmiRNA abundance
appears to occur at relative early “initiator” or “propagatory”
stages of the AD process while NF-kB inhibition may have too
many unwanted off-target effects (Figure 1). In order to address
and implement a successful AM- or NF-kB inhibitor-based
treatment for AD “highly individualistic” or “personalized”
treatment strategies may be required to more effectively address
the specific miRNA deficits of each AD patient, including
combinatorial and/or tailored AM strategies that will take
dedicated care and customization to ensure a successful clinical
outcome.
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